Helen of Troy Q4
This article was originally published in The Rose Sheet
Executive Summary
North American sales from continuing operations, excluding the recently-divested Tactica depilatory business, grew 20.8% in the quarter (ended Feb. 29) to $98.7 mil., driven by strong performances from Vidal Sassoon,Dr. Scholl's,Revlon, Hot Tools and Wigo, firm reports May 13. Net sales from continuing operations grew 25.9% to $112.9 mil. in the quarter, while net earnings increased 92.1% to $16.3 mil. Full year net sales grew 25% to $474.9 mil., and net earnings jumped 89.4% to $71.6 mil. Net earnings including Tactica were up 16.4% to $7.5 mil. in Q4 and increased 56.3% to $60.5 mil. in fiscal 2004. Firm is raising its earnings per diluted share guidance for fiscal 2005 to $2.50-$2.70 from $2.30-$2.40 and expects Q1 2005 sales to increase 8%-16% to $98 mil.-$106 mil...
You may also be interested in...
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.
Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities
Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.